Altan Pharma announces the acquisition of GES Group
Altan Pharma, an Irish speciality pharmaceutical company, has acquired a privately held group of Spanish companies, The GES Group
Altan Pharma, an Irish speciality pharmaceutical company, has acquired a privately held group of Spanish companies, the GES Group.
The GES Group develops, manufactures and markets speciality injectable drugs and consists of three operating companies: GES Genéricos Españoles Laboratorio, Genfarma Laboratorio, and Biomendi.
GES has been providing the Spanish hospital market with a comprehensive line of injectable drugs since 1985. The company is a leading player in the pain and anti-infective segments of the Spanish market and also has an international distribution network covering many European, Latin American and Asian markets.
‘GES is a highly respected leader in the speciality pharmaceutical segment with a reputation for supplying quality injectable products,’ said Guillermo Herrera, Chairman and Chief Executive Officer of Altan. ‘GES' manufacturing expertise and international distribution network provide an attractive foundation to build Altan's global specialty pharmaceutical business.’
